The results indicated that JCT could treat ICS by reducing the symptoms of cerebral infarction and enhancing neuroprotective effects, and its action mechanisms were associated with the activation of the HIF-1α/EPO/VEGFA pathway. The gene discussed is EPO; the disease is brain infarction.